Form 8-K - Current report:
SEC Accession No. 0001193125-24-232306
Filing Date
2024-10-03
Accepted
2024-10-03 17:00:32
Documents
15
Period of Report
2024-10-02
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d828148d8k.htm   iXBRL 8-K 32896
2 EX-3.1 d828148dex31.htm EX-3.1 161488
  Complete submission text file 0001193125-24-232306.txt   397277

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnda-20241002.xsd EX-101.SCH 4192
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vnda-20241002_def.xml EX-101.DEF 14175
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20241002_lab.xml EX-101.LAB 23635
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20241002_pre.xml EX-101.PRE 15208
17 EXTRACTED XBRL INSTANCE DOCUMENT d828148d8k_htm.xml XML 6149
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

EIN.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 241352284
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)